Tumors shrank by at least 30% in five out of 21 pancreatic cancer patients who underwent treatment combining gemcitabine with an agonist CD40 antibody, according to data published in Clinical Cancer Research. The study also found FDG/PET-CT imaging was useful for monitoring patient response. “We’re now using imaging to understand the treatment heterogeneity that one can see in immunotherapy — not all tumors within a patient’s body react the same way, even in the face of powerful treatments, and now we have a way to follow these unique treatment responses in patients in real time,” said researcher Dr. Gregory Beatty. {read more here}